1. Scrip
  2. >>Business
  3. >>Deals

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Protein Degradation Specialist Gets $1bn Up Front

 
• By Mandy Jackson

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Stand out from the crowd
Multiple SERDs are ahead of ARV-471 but Pfizer and Arvinas believe they have a best-in-class estrogen receptor degrader • Source: Alamy

Protein degradation specialist Arvinas, Inc. will receive $1bn up front and accelerate the development of its estrogen receptor protein degrader ARV-471, while Pfizer Inc. gets another opportunity to expand its already significant presence in breast cancer – with the blockbuster CDK4/6 inhibitor Ibrance (palbociclib) – under a deal announced on 22 July for the development and commercialization of Arvinas’ small molecule.

Executives from both companies, during a same-day call with Arvinas investors, acknowledged the competitive environment for the development of oral drugs that degrade the estrogen receptor (ER) in the treatment...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Deal Watch: QurAlis Targets Fragile-X Syndrome In Deals With Quiver, UMass

 
• By Joseph Haas

Plus the end of Sanofi’s six-target alliance with IGM, OmniAb’s deals with Veraxa and Angelini, alliances involving Skye/Arecor, Genprex/UTHealth Houston and more.

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth.

Gilead Ready To Go After Hepatitis D Again

 
• By Joseph Haas

Following an FDA complete response in 2022, Gilead is getting ready to refile bulevirtide for hepatitis D. The drug already is approved in the EU, UK and elsewhere.

Progress In The Effort To Improve Outcomes In SCLC

 
• By Jessica Merrill

Several drug makers are working to bring new advances to small-cell lung cancer, a fast-growing cancer with limited treatment options.